News tagged ‘BasicResearch’ clear
A new Dana-Farber study shows a “big picture” view of an overactive B cell receptor (BCR) signaling pathway that drives about one-third of Diffuse Large B-Cell Lymphomas, which could lead to more promising genetic targets for drug development.
Tags: BasicResearch, Lymphoma
The Leukemia & Lymphoma Society and Dana-Farber joined together to establish the Blood Cancer Research Partnership, an innovative program bringing together a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.
Tags: BasicResearch, Leukemia, Lymphoma
Dana-Farber researchers found that combining the immune stimulator GM-CSF with the antibody drug ipilimumab prolonged survival in patients with metastatic melanoma and reduced the incidence of the most serious side effects.
Tags: BasicResearch, Melanoma
Dana-Farber researchers reported that patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene responded better to targeted therapy than traditional chemotherapy.
Tags: BasicResearch, LungCancer, TargetedTherapy
A Dana-Farber and Harvard School of Public Health study finds that most young women with breast cancer chose to have a mastectomy rather than a surgical procedure that would conserve the breast.
Tags: BasicResearch, BreastCancer
Dana-Farber investigators led a phase 1 trial in which a new oral targeted drug, idelalisib, (GS-1101), showed the potential to stave off the need for additional treatments for relapsed or treatment-resistant CLL.
Tags: BasicResearch, Leukemia
A type of low-grade but sometimes lethal brain tumor in children has been found to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors.
Tags: BasicResearch, ChildhoodCancer, BrainTumors
Dana-Farber researchers detail how low doses of interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD) and possibly lead to better treatment for other immune disorders.
Tags: BasicResearch, GraftVersusHost
An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Tags: BasicResearch, ChildhoodCancer
Showing 1-10 of 120 items